Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05858645
PHASE4
Correction of Psoriatic T Cell Signatures by Deucravacitinib
Sponsor: University of California, San Francisco
View on ClinicalTrials.gov
Summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
25
Start Date
2023-10-01
Completion Date
2026-06
Last Updated
2024-06-27
Healthy Volunteers
No
Conditions
Interventions
DRUG
deucravacitinib
Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment
Locations (1)
University of California, San Francisco
San Francisco, California, United States